Actively Recruiting
Determining the Effectiveness of Remote Monitoring of Cancer Patients With Oral Cancer Treatment Using Caaring® Software
Led by Persei Vivarium · Updated on 2025-05-31
194
Participants Needed
3
Research Sites
16 weeks
Total Duration
On this page
Sponsors
P
Persei Vivarium
Lead Sponsor
E
Effice Servicios Para la Investigacion S.L.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial investigation with device is to determinate the efficacy of the remote monitoring in cancer patients with a software called Caaring® a través del cumplimento terapéutico y de dosis. The main question it aims to answer is if the development of a self-management platform (Caaring®) empowers cancer patients throughout their illness, reducing the number of in-person and telephone visits assisted by specialized medical and nursing staff. For this, researchers will compare the assessments between the two groups. This is a randomized study with two arms. Online telemonitoring group: The follow-up of these patients will be carried out prospectively remotely through the Caaring® platform. And Prospective Control group: The data of these patients are collected prospectively for their routine medical visits for 12 weeks after their inclusion. Caaring group patients must have sufficient technological skills to use a smartphone.
CONDITIONS
Official Title
Determining the Effectiveness of Remote Monitoring of Cancer Patients With Oral Cancer Treatment Using Caaring® Software
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who provide informed consent.
- Age 18 years or older.
- Oncology patients undergoing active outpatient oral therapy with capecitabine, cyclin inhibitors, hormonal therapies, TKI inhibitors, or monotherapy with or without intravenous therapy.
- Oncology patients expected to continue active outpatient oral oncology treatment for at least 12 weeks after inclusion.
- Patients who demonstrate sufficient technological skills to use a smartphone.
- Patients who do not meet exclusion criteria.
You will not qualify if you...
- Patients with cognitive or sensory difficulties or insufficient command of Spanish language that impair understanding of study questionnaires, unless they have a legal representative.
- Patients unlikely to complete follow-up due to change of residence.
- Patients participating in other clinical trials or experimental studies at the time of recruitment (observational studies allowed).
- Patients with primary diagnosis of mental illness or poorly controlled medical condition.
- Terminally ill patients or those receiving palliative care as defined by SECPAL.
- Institutionalized patients.
- Patients receiving specific follow-up care in other units requiring hospital visits less often than every two months (e.g., hemodialysis, transplants).
- Patients who do not demonstrate sufficient technological skills to use a smartphone.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Hospital Universitario HM Monteprincipe
Boadilla del Monte, Madrid, Spain, 28660
Actively Recruiting
2
Hospital Universitario HM Sanchinarro
Hortaleza, Madrid, Spain, 28050
Actively Recruiting
3
Hospital Universitario HM Puerta del Sur
Móstoles, Madrid, Spain, 28938
Actively Recruiting
Research Team
R
Roberto Bravo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here